Phase 1 Control Clinical Trials
18 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–18 of 18 trials
Recruiting
Phase 1
OMAR Opioid Use Disorder
Healthy Control
Yale University30 enrolled1 locationNCT05683184
Recruiting
Phase 1
Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study
Impulse Control Disorder
M.D. Anderson Cancer Center30 enrolled1 locationNCT06639594
Recruiting
Phase 1
Controlled Human Infection Study of Orally Administered Trichuris Trichiura Eggs in Naïve Adults
WhipwormTrichuriasisControlled Human Infection
George Washington University18 enrolled2 locationsNCT05706116
Recruiting
Phase 1
SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
Uncontrolled Hypertension
Shenzhen Salubris Pharmaceuticals Co., Ltd.82 enrolled1 locationNCT07051603
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine 40 mg capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine 40 mg capsule conducted under fasting condition and at steady state in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12618000563268
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine 15 mg capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine 15 mg capsule conducted under fasting condition in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12618000423213
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine capsule conducted under fasting condition in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12618000308291
Completed
Phase 1
A phase 1, randomized, double-blind, placebo-controlled, sequential-panel, ascending single-dose study to evaluate the safety, tolerability, and pharmacokinetics of intravenous CMX-020 in healthy male and female subjects
Pain Control
Cytometix Inc48 enrolled1 locationACTRN12617001583336
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine capsule conducted under fed condition in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited20 enrolled1 locationACTRN12617001555347
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 15 mg alpha,alpha-dimethylphenethylamine tablet against the innovator 15 mg alpha,alpha-dimethylphenethylamine capsule conducted under fasting conditions in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001384347
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of alpha,alpha-dimethylphenethylamine tablet against the innovator alpha,alpha-dimethylphenethylamine capsule conducted under fasting conditions and at steady state in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001321336
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of alpha,alpha-dimethylphenethylamine tablet against the innovator alpha,alpha-dimethylphenethylamine capsule conducted under fed conditions in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corp Ltd24 enrolled1 locationACTRN12617001314314
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of alpha,alpha-dimethylphenethylamine tablet against the innovator alpha,alpha-dimethylphenethylamine capsule conducted under fasting conditions in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001303336
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 2-methyl-1-phenylpropan-2-amine (122-09-8) capsule against the innovator 2-methyl-1-phenylpropan-2-amine (122-09-8) capsule conducted under fed condition in healthy male and female volunteers.
2-methyl-1-phenylpropan-2-amine (122-09-8) is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001093370
Recruiting
Phase 1
The impact of Sulpiride (600mg; a dopamine antagonist) on behavioural and electrophysiological measures of visuospatial attention and inhibition
Inhibitory Control DeficitsSpatial Attention Deficits
Professor Mark Bellgrove50 enrolled1 locationACTRN12617000652370
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of phentermine capsule against the innovator phentermine capsule conducted under fed conditions in healthy male and female volunteers in a pilot study
Bioequivalence pilot study conducted in healthy volunteers comparing two formulations of phentermine with no health condition or problem studied.
Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, phentermine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corp Ltd10 enrolled1 locationACTRN12617000172303
Completed
Phase 1
The link between impulsivity and dopamine
Impulse control disorders in Parkinson's disease patients taking dopaminergic medication
Professor Winston Byblow60 enrolled1 locationACTRN12614000046606
Completed
Phase 1
Avastin in the prevention of postoperative scarring after glaucoma filtration surgery.
Glaucoma, uncontrolled intraocular eye pressure, trabeculectomy, postoperative intervention, subconjunctival delievery.
Monash Universtity50 enrolled1 locationACTRN12607000318482